Conference Coverage
Conference Coverage
NIPPV Benefits Seen in Severe Stable COPD
Major Finding: Noninvasive positive pressure ventilation (NIPPV) was associated with a significant decrease in ICU admissions at 1 year (odds...
Conference Coverage
Handling Vaccines Won't Immunize Practices Against Financial Risk
Conference Coverage
Evidence Backs Some Drugs for Hidradenitis Suppurativa
Conference Coverage
Sildenafil Protects Sexual Function Following Prostate Radiation
Major Finding: Overall total International Index of Erectile Function scores were significantly higher among men who took sildenafil at 6 (P = ....
Conference Coverage
RELAX-AHF: Serelaxin Promising for Acute Heart Failure
Major Finding: Forty-eight hours of treatment with intravenous serelaxin in patients with acute heart failure was associated with a 37% reduction...
Conference Coverage
Tacrolimus 0.03% Favored for Atopic Blepharoconjunctivitis
Major Finding: The conjunctivitis response rates were 80%, 55%, and 50% with tacrolimus, pimecrolimus, and topical steroids, respectively.
Conference Coverage
Left-Atrial MAZE Ablation Compromises Atrial Function
Major Finding: Full left-atrial ablation produced statistically significant impairments of left-atrial function, including an average 20% drop in...
Conference Coverage
Merkel Cell Carcinoma Prognosis Linked to Vitamin D
Major Finding: Vitamin D deficiency was found in nearly two-thirds of a large group of patients with Merkel cell carcinoma, and their outcomes...
Conference Coverage
Chelation Trial: Results Positive but Not Practice Changing
Major Finding: Post-MI patients who received chelation therapy had 39 fewer cardiovascular events than did those receiving placebo, a...
Conference Coverage
Platelet Activity, Clinical Benefit Disconnected Post ACS
Major Finding: Patients on prasugrel had significantly lower platelet activity than clopidogrel-treated patients, but this did not produce better...
Conference Coverage
AMG145 Delivers Robust Results for Statin-Intolerant Patients
Major Finding: At 12 weeks, the mean change in LDL cholesterol from baseline with 420 mg AMG145 was –51% as monotherapy and –63% as combination...